Navigation Links
Bone Marrow Cancer Patients May Benefit From Drug Combo
Date:3/29/2010

Small study had successful results in myelodysplastic syndrome patients

MONDAY, March 29 (HealthDay News) -- The drugs azacitidine and lenalidomide provide a highly effective combination treatment for bone marrow cancer, according to the results of a new study.

The phase 1 study, which was funded by the U.S. National Institutes of Health, included 18 higher-risk patients, median age 68, with myelodysplastic syndromes (MDS). In people with this cancer (which is similar to leukemia), stem cells fail to mature into healthy red blood cells, white blood cells or platelets. This leads to infection, anemia and bleeding complications.

The patient response rate to the combined drug treatment was 67 percent, and the treatment was well-tolerated. The combined treatment had a better response rate and remission rate than either drug used alone.

This is the first time that two U.S. Food and Drug Administration-approved drugs have been combined for the treatment of MDS. The findings were published online March 29 in the Journal of Clinical Oncology.

"This combination was so successful, it's being incorporated into the next nationwide MDS study, as well as international studies," study author Dr. Mikkael Sekeres, of the Taussig Cancer Institute at the Cleveland Clinic, said in a news release.

About 15,000 people are diagnosed with MDS each year in the United States, and about 60,000 are living with the disease. MDS primarily affects older adults.

More information

The American Cancer Society has more about myelodysplastic syndromes.



-- Robert Preidt



SOURCE: Cleveland Clinic, news release, March 29, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Page: 1

Related medicine news :

1. Stem Cell, Bone Marrow Transplants Both Benefit Leukemia Patients
2. Stem cell breakthrough: Bone marrow cells are the answer
3. Bone Marrow Transplants May Cure Sickle Cell in Adults
4. Mayo Clinic Proceedings: Researchers find evidence of survival gains in bone marrow disease
5. Drug dramatically reduces nausea and vomiting in bone marrow transplant patients
6. HIV Hides Out in Bone Marrow Cells
7. University of Michigan scientists discover bone marrow can harbor HIV-infected cells
8. Fewer platelets could be used for some cancer and bone-marrow transplantation patients
9. Autologous Bone Marrow Stem Cells Transplant into Parkinson's Disease Patients is Safe and May Improve Their Quality of Life
10. Vertebroplasty: Integral to treating back pain in blood marrow cancer patients
11. Targeted therapy prolongs life in patients with HER2-positive breast cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... December 07, 2016 , ... DrugDev again demonstrated its dedication ... one of the early adopters completing EU-U.S. Privacy Shield Certification from the U.S. Department ... on both sides of the Atlantic with a mechanism to comply with EU data ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... ... (NYLF): Medicine will have the unique opportunity to get hands-on experience in ... high school students an immersive experience to gain invaluable, real-life medical skills that ...
(Date:12/7/2016)... ... 07, 2016 , ... "Today, MHA and mental health advocates ... systems reform legislation in more than fifty years. We applaud the bipartisan action ... elected officials to improving mental health services and supports in our nation. , ...
(Date:12/7/2016)... (PRWEB) , ... December 07, 2016 , ... Kenall Manufacturing, ... new MedMaster™ MPCNGX . The MPCNGX is a multi-function, sealed, LED luminaire that ... amount of light where and when it’s needed. , A 2’ x ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... in their bodies, a researcher at the Icahn School of Medicine at Mount ... The study found that when young children are exposed to secondhand marijuana smoke, ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... , Dec. 7, 2016   IQuity, Inc., ... that Don Hardison has been ... an executive with extensive experience as CEO, ... and Fortune 500 companies within the molecular, clinical ... extensive marketing and sales experience within the pharmaceutical ...
(Date:12/7/2016)... "Lantus (Insulin Glargine) Biosimilar Clinical Trial & Opportunity Insight" report by PNS ... in clinical pipeline. Currently 5 biosimilar version of Lantus are commercially available ... Kenya , Czech Republic , ... , Slovakia , United Kingdom ... on Lantus expired in 2014. Lantus is the brand name for ...
(Date:12/7/2016)... Dec. 7, 2016 KEY FINDINGS ... benefits such as reducing loss of blood during ... cardiac arrests, rapid recovery after surgeries, and decreasing ... be segmented into convective warming system, surface warming ... turn reduce the stay at hospitals thus, lowering ...
Breaking Medicine Technology: